Hadlinol (Fluconazole)

Hadlinol is indicated for several fungal infections where fluconazole is an accepted therapy.

• Oropharyngeal and esophageal candidiasis.
• Vaginal candidiasis (yeast infection).
• Cryptococcal meningitis, often in immunocompromised patients.
• Systemic mycoses caused by susceptible Candida species.
• Prophylaxis of fungal infections in patients undergoing bone‑marrow transplantation (off‑label in some regions).
• Dermatophyte infections of the skin and nails (off‑label).
• Prevention of recurrent vulvovaginal candidiasis in women with a history of multiple episodes. The medication may be prescribed for acute treatment as well as for longer‑term suppression in patients at risk of recurrent infection, following clinical assessment.

Side effects associated with fluconazole, the active ingredient in Hadlinol, are generally dose‑dependent and may appear during short‑term or prolonged therapy. Most patients experience mild, self‑limiting symptoms, while a smaller proportion may develop serious adverse reactions that require medical attention.

Common

• Nausea or vomiting, often mild and transient.
• Headache or dizziness, which may resolve without intervention.
• Abdominal discomfort or diarrhea, typically short‑lasting.

Serious

• Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, which can be life‑threatening.
• Hepatotoxicity manifested by elevated liver enzymes, jaundice, or acute liver failure, requiring immediate discontinuation.
• Allergic reactions including anaphylaxis, angioedema, or severe rash, which may necessitate emergency care.

When prescribing Hadlinol, clinicians consider several precautionary measures to minimize risk and ensure safe use.

• Assess liver function before initiating therapy and monitor periodically during treatment.
• Use caution in patients with known hypersensitivity to azole antifungals or fluconazole.
• Adjust dose or avoid use in individuals with severe renal impairment, as fluconazole is renally excreted.
• Review concomitant medications for potential QT‑prolonging effects, especially in patients with cardiac arrhythmias.
• Avoid use during pregnancy unless the benefit outweighs potential risk, due to limited safety data.
• Counsel patients to report signs of severe skin reactions, liver dysfunction, or allergic responses promptly.

Fluconazole can affect the metabolism of many drugs; reviewing a patient’s medication list helps prevent adverse interactions.

Avoid

• Avoid concomitant use with strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce fluconazole efficacy.
• Avoid simultaneous administration with medications that significantly prolong the QT interval (e.g., cisapride, pimozide) due to additive cardiac risk.

Use with caution

• Use with caution when co‑administered with warfarin or other anticoagulants, as fluconazole may increase plasma concentrations and bleeding risk.
• Use with caution with oral hypoglycemic agents (e.g., sulfonylureas) because fluconazole can enhance hypoglycemic effects.
• Use with caution with statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin) due to possible increased risk of myopathy.